drugset / Trial / NCT02195804

Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers

NCT02195804

Phase 1 Completed 42 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to establish the relative bioavailability (BA) of two different ranitidine hydrochloride 150 mg ODT formulation in comparison to the current, over the counter (OTC) ranitidine hydrochloride (Maximum Strength ZANTAC 150®) formulation following oral single dose administration in fasting healthy male volunteers

Timeline

Start
2009-05
Primary completion
2009-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranitidine Unknown 150 mg Oral

Indications

No indication recorded.